MedTrace Logo

Study to Investigate the Safety, Tolerability and Activity of AZD5069 When Given as a Single Dose to Healthy Male and/or Female Subjects

NCT00953888 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 203

Last updated 2015-06-25

No results posted yet for this study

Summary

The purpose of this study is to determine how well tolerated and safe AZD5069 is at different dose levels in healthy male and/or females. The study will also investigate how quickly AZD5069 is absorbed into and cleared by the body.

Conditions

  • Healthy

Interventions

DRUG

AZD5069

Single dose of oral solution.

DRUG

Placebo

Single dose of oral solution.

Sponsors & Collaborators

Principal Investigators

  • Andrew Sparrow, BSc, BMedSci, BM,BS · AstraZeneca Clinical Pharmacology Unit, Queens Medical Centre, Nottingham NG7 2UH

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-07-31
Primary Completion
2009-12-31
Completion
2009-12-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00953888 on ClinicalTrials.gov